Aim: Evaluate quality of life (QoL) in patients with advanced non-small cell lung cancer treated with second or third line nab-paclitaxel +/- durvalumab. Patients & methods: Longitudinal QoL was assessed using Lung Cancer Symptom Scale, EuroQoL Five-Dimensions Five-Levels and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core. Results: QoL was generally stable through eight treatment cycles (both arms). Clinically meaningful improvement from baseline was noted in Lung Cancer Symptom Scale (overall constitutional score and three-item index [nab-paclitaxel + durvalumab]) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core (global health status/QoL and emotional functioning [both arms] and pain [nab-paclitaxel + durvalumab]) analyses. EuroQoL Five-Dimensions Five-Levels domains were stable/improved or completely resolved at least once in 19-56% and 9-51% of patients, respectively. Conclusion: While QoL trends were promising, additional data are required to support these regimens in this setting.
- Ponce Aix, S.
- Talbot, D.
- Govindan, R.
- Dols, M. C.
- Postmus, P. E.
- Lewanski, C.
- Bennouna, J.
- Fischer, J. R.
- Juan-Vidal, O.
- Stewart, D. J.
- Ardizzoni, A.
- Bhore, R.
- Wolfsteiner, M.
- Reck, M.
- Ong, T. J.
- Morgensztern, D.
Keywords
- Eortc qlq-c30
- Eq-5d-5l
- durvalumab
- lung cancer symptom scale
- nab-paclitaxel
- non-small cell lung cancer
- quality of life
